Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOCORP : Wins the Pharmapack Award for Its Smart Sensor, Easylog

share with twitter share with LinkedIn share with facebook
02/11/2016 | 12:01pm EDT

Regulatory News:

BIOCORP, (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices announces today that it has won the Best Exhibitor Innovation Award presented by Pharmapack Europe 2016 rewarding Easylog, Biocorp’s smart sensor. The ceremony was held on February, 11th at Paris Expo.

The Awards are organized alongside the Pharmapack Europe conference and exhibition each year from its inception in 1997 onwards, and reward the best innovations in the pharmaceutical industry every year.

Biocorp’s smart sensor Easylog has received an award in the category Best Exhibitor Innovation for “customization and user-friendliness” acknowledged for being an intuitive real time monitoring tool for patients and health care professionals.

EasyLog, a smart sensor for drug delivery systems

Easylog is a smart sensor that converts all insulin delivery devices, reusable as well as disposable, into internet-connected and communicating devices. Easylog mobile application provides users with reminders for drug delivery, alerts in case of double injection, real-time access to patients’ historical data and personalized logbook.
Easylog is an innovative solution that meets the challenges of personalized medicine and is a crucial tool to ensure the highest quality of treatment against chronic diseases, improving the patient’s comfort and providing relevant information for treatment follow-up to healthcare professionals.

Back in 2015, Biocorp had already been awarded by Pharmapack for its Datapen, a connected injector pen.

« We are very honored to receive this new Award presented by Pharmapack Europe. Following Datapen in 2015, it is the turn of our Easylog smart sensor to be in the public eye. Easylog is a unique solution that contributes to the increase of the compliance rates, which are still very low among patients suffering from chronic diseases. Our contribution in this field aims to improve the patient’s comfort and data reliability for all stake holders. We are extremely proud to receive the Pharmapack Award which highlights once again our innovations and the major progress they bring”, commented Jacques Gardette, Biocorp’s CEO and founder.

More information: http://www.biocorpsys.com/treatment-management-solutions


Coinciding with Pharmapack Europe Exhibition since its first edition in 1997, the Pharmapack Awards have been rewarding the best innovations in the pharmaceutical industry every year.

In 2016, Pharmapack Europe awarded two categories within the framework of the Pharmapack Awards:

  • Best Health Products: This award category is dedicated to the visitors' innovations. The prize will reward the pharma companies and the suppliers that they have worked with to develop the product. It can be a health product launch or an enhancement of an existing product for which the packaging has been improved.
  • The Exhibitor Innovation: This award will recognize the best innovations among the exhibitors' innovations displayed in the Innovation Gallery. The jury is made up of over 380 companies. The award ceremony was held by decisions makers in the pharmaceutical R&D and purchasing for packaging fields.

More information: http://www.pharmapackeurope.com/europe/enter-awards


Founded in 2004 in Issoire (near Clermont-Ferrand, France), Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees.

Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR). For more information, please visit: www.biocorp.fr

Follow us on Twitter @BIOCORPSystems

© Business Wire 2016
share with twitter share with LinkedIn share with facebook
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
04/09BIOCORP : 2019 annual results
04/09BIOCORP : 2019 Annual Results
04/09BIOCORP : Annual results
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
02/12BIOCORP : Strong Revenue Growth In 2019
More news
Sales 2020 15,3 M 17,2 M 17,2 M
Net income 2020 0,60 M 0,68 M 0,68 M
Net cash 2020 1,17 M 1,32 M 1,32 M
P/E ratio 2020 180x
Yield 2020 0,06%
Capitalization 111 M 126 M 126 M
EV / Sales 2019
EV / Sales 2020 7,23x
Nbr of Employees 52
Free-Float 51,3%
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 27,00 €
Spread / Highest target 18,5%
Spread / Average Target 16,1%
Spread / Lowest Target 13,7%
EPS Revisions
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-2.32%375 087
ROCHE HOLDING AG5.75%300 427
MERCK & CO., INC.-15.64%193 674
NOVARTIS AG-10.77%192 177
PFIZER, INC.-13.65%187 920